Our in vitro data are strongly supported by in vivo results, which show that G1 significantly inhibits tumor growth of HCC xenografts through the GPER/EGFR/ERK axis, and that the specific activation of the GPER/ERK pathway notably enhances tumor reduction. The gene discussed is GPER1; the disease is neoplasm.